Our December 2021 question asks, “The resident orders a thrombosis risk profile on an inpatient being treated for a pulmonary embolism [PE]. How do you respond?” This question is inspired by a case study we developed for Rutgers’ CLSC 5124 Advanced Hemostasis fall, 2021 online graduate course. Above is a screen capture that lists several potential members of a thrombosis risk profile taken from a 2018 lecture George presented in Portland, ME. The optional, or possibly obsolete assays are factor VIII activity, lipoprotein (a) [Lp(a)], homocysteine, methylenetetrahydrofolate resistance 667 polymorphism [MTHFR 667], and two recently described polymorphisms, factor IX Padua and thrombin [factor II] antithrombin resistance. The starred assays are excluded if there has been a thrombotic event or if anticoagulant therapy has been in effect in the previous 10–14 days.
Please select your answer from the Quick Question panel on your right, and as always, offer your comments about this provocative subject below.